Dimerix Stock

Dimerix Current Liabilities

The Current Liabilities of Dimerix (DXB.AX) as of Sep 3, 2026 is 22.16 M AUD. In the previous year, Current Liabilities was 3.36 M AUD — a change of 558.74% (higher).

Current Liabilities

22.16 MAUD

YoY

558.74%

Last updated:

Current Liabilities of Dimerix is 2026 22.16 M AUD. Current Liabilities of Dimerix was 2025 3.36 M AUD. It decreases by 558.74% higher compared to the previous year.

The Dimerix Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
406,700.00 AUD
Jan 1, 2019
737,800.00 AUD
Jan 1, 2020
2.63 M AUD
Jan 1, 2021
7.95 M AUD
Jan 1, 2022
2.02 M AUD
Jan 1, 2023
11.76 M AUD
Jan 1, 2024
3.36 M AUD
Jan 1, 2025
22.16 M AUD
The Dimerix Current Liabilities history
YEARCurrent LiabilitiesYoY
22.16 MAUD+558.74%
3.36 MAUD-71.39%
11.76 MAUD+480.96%
2.02 MAUD-74.55%
7.95 MAUD+202.39%
2.63 MAUD+256.44%
737,800.00AUD+81.41%
406,700.00AUD+67.92%
242,200.00AUD-14.36%
282,800.00AUD+47.52%
191,700.00AUD+379.25%
40,000.00AUD-20.00%
50,000.00AUD+66.67%
30,000.00AUD0.00%
30,000.00AUD-25.00%
40,000.00AUD-20.00%
50,000.00AUD-96.53%
1.44 MAUD-4.00%
1.50 MAUD+328.57%
350,000.00AUD+45.83%
240,000.00AUD-79.83%
1.19 MAUD-3.25%
1.23 MAUD-7.52%
1.33 MAUD-16.35%
1.59 MAUD—
Access this data via the Eulerpool API
Get Free API Key

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Current Liabilities of Dimerix is 22.16 M AUD in 2026.

Current Liabilities of Dimerix changed from 3.36 M AUD to 22.16 M AUD, representing a 558.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Dimerix since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Dimerix historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Dimerix

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Dimerix